Nothing Special   »   [go: up one dir, main page]

USRE46218E1 - Process for the synthesis of agomelatine - Google Patents

Process for the synthesis of agomelatine Download PDF

Info

Publication number
USRE46218E1
USRE46218E1 US14/619,284 US201214619284A USRE46218E US RE46218 E1 USRE46218 E1 US RE46218E1 US 201214619284 A US201214619284 A US 201214619284A US RE46218 E USRE46218 E US RE46218E
Authority
US
United States
Prior art keywords
compound
formula
process according
yield
subjected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US14/619,284
Inventor
Samir Zard
Béatrice Sire
Mehdi Boumediene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44088993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE46218(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Priority to US14/619,284 priority Critical patent/USRE46218E1/en
Application granted granted Critical
Publication of USRE46218E1 publication Critical patent/USRE46218E1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/06Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C07C2102/10
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to a new process for the industrial synthesis of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, of formula (I):
  • Agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, has valuable pharmacological properties.
  • Patent specification EP 0 447 285 describes production of agomelatine in eight steps starting from 7-methoxy-1-tetralone.
  • This synthesis route is based on carrying out free radical reactions that are not very commonly used but are nevertheless very effective. Converting these reactions to the industrial scale using continuous-flow reactors is promising as it becomes simpler to control propagation of the chain reaction.
  • agomelatine can accordingly be synthesised in 6 steps in the course of which only two of the intermediates are isolated.
  • the present invention relates to a process for the industrial synthesis of the compound of formula (I):
  • Xa represents a group —S—C(S)—OR in which R represents a linear or branched (C 1 -C 6 )alkyl group,
  • the compound of formula (VII) is then subjected to reduction using hydrogen in the presence of Raney nickel in an ammoniacal ethanol medium and then converted into a salt using hydrochloric acid to yield the compound of formula (VIII):
  • the compound of formula (VII) can be subjected to reduction by hydrogen in the presence of Raney nickel in a medium comprising acetic anhydride in a polar protic medium to yield the compound of formula (I), which is isolated in the form of a solid.
  • Xa represents a group —S—C(S)—OC 2 H 5 .
  • initiation of the free radical reactions is carried out by thermal means.
  • the reaction mixture is heated to a temperature of from 50° C. to 140° C.
  • cyclisation is carried out at a temperature of from 130 to 135° C.
  • Peroxides are free radical initiators that are especially suitable for carrying out the step of addition of the compound of formula (II) to the compound of formula (III), or for performing cyclisation of the compound of formula (IV) to form the compound of formula (V).
  • diisobutyryl peroxide cumyl peroxyneodecanoate, tert-amyl peroxyneodecanoate, di(2-ethylhexyl)peroxydicarbonate, tert-butyl peroxyneodecanoate, dibutyl peroxydicarbonate, dicetyl peroxydicarbonate, dimyristyl peroxydicarbonate, tert-butyl peroxyneoheptanoate, tert-amyl peroxypivalate, didecanoyl peroxide, tert-amyl peroxy-2-ethylhexanoate, tert-butyl peroxyis
  • the reaction is initiated in the presence of dilauroyl peroxide.
  • the amount of dilauroyl peroxide used in the cyclisation is preferably from 1 to 2.5 equivalents.
  • dilauroyl peroxide is added to the medium in stages.
  • the addition and/or cyclisation reactions are carried out in a solvent customarily used in free radical chemistry such as 1,2-dichloroethane, dichloromethane, benzene, toluene, trifluoromethylbenzene, chlorobenzene, hexane, cyclohexane, heptane, octane, ethyl acetate, tert-butyl alcohol, and mixtures thereof.
  • free radical chemistry such as 1,2-dichloroethane, dichloromethane, benzene, toluene, trifluoromethylbenzene, chlorobenzene, hexane, cyclohexane, heptane, octane, ethyl acetate, tert-butyl alcohol, and mixtures thereof.
  • Conversion of the compound of formula (V) into the compound of formula (VI) is advantageously carried out in the presence of a Lewis acid such as aluminium isopropoxide or samarium isopropoxide. This conversion is moreover preferably carried out in an alcohol (primary or secondary), and even more preferably in isopropanol.
  • a Lewis acid such as aluminium isopropoxide or samarium isopropoxide.
  • a catalytic amount of p-toluenesulphonic acid is added to the mixture once all the tetralone (V) has been consumed at the end of conversion of the compound of formula (V) into the compound of formula (VI).
  • Aromatisation of compound (VI) is carried out in the presence of a quinone, preferably in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or tetrachlorobenzoquinone (TCQ). Even more preferably, aromatisation is carried out in the presence of TCQ at the reflux of toluene.
  • DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
  • TCQ tetrachlorobenzoquinone
  • Example 2 corresponds to the same reaction route as that used in Example 1 but with the difference that only (7-methoxy-1,2-dihydro-1-naphthyl)acetonitrile and (7-methoxy-1-naphthyl)acetonitrile were isolated.
  • Step A S-[1-(cyanomethyl)-4-(4-methoxyphenyl)-4-oxobutyl]-O-ethyl dithiocarbonate
  • Step B (7-Methoxy-4-oxo-1,2,3,4-tetrahydro-1-naphthyl)acetonitrile
  • Step A The compound of Step A, used directly without having been purified, is redissolved in chlorobenzene (900 mL) and the solution is refluxed for 15 minutes under a nitrogen atmosphere. Dilauroyl peroxide is then gradually added to the solution under reflux (10 mol % every 10 minutes). When the reaction is complete, the mixture is cooled to ambient temperature and concentrated under reduced pressure. Acetonitrile is then introduced in order to cause a large part of the dilauroyl peroxide compounds to precipitate out. The mixture is then filtered, concentrated under reduced pressure and purified by flash column chromatography (petroleum ether-ethyl acetate: 60-40) to yield the title compound in solid form in a yield of 40%.
  • Aluminium isopropoxide (2.05 g, 10.0 mmol) is added to a solution of the compound obtained in Step B (680 mg, 3.15 mmol) in isopropanol (15 mL) at ambient temperature.
  • the reaction mixture is refluxed.
  • a few crystals of p-toluenesulphonic acid monohydrate are added and a Dean-Stark apparatus is mounted on top of the flask.
  • the mixture is again refluxed for 1 hour, during which the isopropanol is gradually replaced with toluene by means of the Dean-Stark apparatus.
  • a 1N HCl solution is then added and the resulting phases are separated.
  • the aqueous phase is extracted with ethyl acetate, the organic phases being washed with saturated NaHCO 3 solution and with saturated NaCl solution, then dried over MgSO 4 , filtered and concentrated under reduced pressure.
  • the residue is purified by column chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in the form of an oil in a yield of 85%.
  • the reaction was carried out on a larger batch in order to optimise the yield obtained: 136 g of Raney nickel, 2.06 L of ethanol and 0.23 L of water are introduced into an 8 L reactor. Whilst stirring at 70° C. and under 30 bars of hydrogen, the compound obtained in Step D (0.8 kg) dissolved in acetic anhydride (2.4 L) is slowly added. At the end of the addition, the reaction mixture is stirred for 1 hour under hydrogen at 30 bar, the reactor is then decompressed and the liquors are filtered. After concentration of the mixture, the residue is crystallised from a mixture of ethanol/water 35/65 to yield the title product in a yield of 89% and with a chemical purity greater than 99%.
  • the crude mixture is redissolved in chlorobenzene (640 mL) and the solution is refluxed for 15 minutes under a nitrogen atmosphere. Dilauroyl peroxide is then gradually added to the solution under reflux (10 mol % every 10 minutes). When the reaction is complete, the mixture is cooled to ambient temperature and concentrated under reduced pressure. Acetonitrile is then introduced in order to cause a large part of the dilauroyl peroxide compounds to precipitate out. The mixture is then filtered and concentrated under reduced pressure. Half the crude oil thereby obtained is redissolved in isopropanol (100 mL) at ambient temperature in the presence of aluminium isopropoxide (13.6 g, 66.6 mmol). The reaction mixture is refluxed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Process for the industrial synthesis of the compound of formula (I)
Figure USRE046218-20161129-C00001

Description

This application is a 371 of PCT/FR12/00005, filed Jan. 4, 2012.
The present invention relates to a new process for the industrial synthesis of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, of formula (I):
Figure USRE046218-20161129-C00002
Agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, has valuable pharmacological properties.
It has, in fact, the double characteristic of being, on the one hand, an agonist of receptors of the melatoninergic system and, on the other hand, an antagonist of the 5-HT2C receptor. These properties provide it with activity in the central nervous system and, more especially, in the treatment of major depression, seasonal affective disorder, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet-lag, appetite disorders and obesity.
Agomelatine, its preparation and its use in therapeutics have been described in European patent specifications EP 0 447 285 and EP 1 564 202.
In view of the pharmaceutical value of this compound, it has been important to be able to produce it using an effective industrial synthesis process which is readily transferable to the industrial scale and which provides agomelatine in a good yield and with excellent purity.
Patent specification EP 0 447 285 describes production of agomelatine in eight steps starting from 7-methoxy-1-tetralone.
In patent specification EP 1 564 202, the Applicant developed a new, much more effective and industrialisable synthesis route in only four steps starting from 7-methoxy-1-tetralone that makes it possible to obtain agomelatine in highly reproducible manner in a well-defined crystalline form.
However, the search for new synthesis routes, especially starting from starting materials that are less costly than 7-methoxy-1-tetralone, is currently still relevant.
The Applicant has continued his investigations and has developed a new process for the synthesis of agomelatine starting from allyl cyanide and a xanthate compound: these new starting materials have the advantage of being simple and readily obtainable in large quantities at less cost.
This synthesis route is based on carrying out free radical reactions that are not very commonly used but are nevertheless very effective. Converting these reactions to the industrial scale using continuous-flow reactors is promising as it becomes simpler to control propagation of the chain reaction.
This new process moreover makes it possible to obtain agomelatine in reproducible manner and without requiring laborious purification, with a purity that is compatible with its use as a pharmaceutical active ingredient. Indeed, agomelatine can accordingly be synthesised in 6 steps in the course of which only two of the intermediates are isolated.
More specifically, the present invention relates to a process for the industrial synthesis of the compound of formula (I):
Figure USRE046218-20161129-C00003
which process is characterised in that allyl cyanide of formula (II):
Figure USRE046218-20161129-C00004
is reacted, in the presence of a free radical initiator, with a compound of formula (III):
Figure USRE046218-20161129-C00005
wherein Xa represents a group —S—C(S)—OR in which R represents a linear or branched (C1-C6)alkyl group,
to yield the compound of formula (IV):
Figure USRE046218-20161129-C00006
wherein Xa is as defined hereinbefore,
it being possible for this latter compound optionally to be isolated, before being subjected to a cyclisation reaction in the presence of a free radical initiator in order to form the compound of formula (V):
Figure USRE046218-20161129-C00007
which compound of formula (V) also optionally may be isolated,
which is subjected to a reduction-dehydration reaction to yield the compound of formula (VI):
Figure USRE046218-20161129-C00008
which is then subjected to an aromatisation reaction to yield the compound of formula (VII):
Figure USRE046218-20161129-C00009
which is subjected to reduction using hydrogen in the presence of Raney nickel in a polar protic medium and to reaction with acetic anhydride to yield the compound of formula (I), which is isolated in the form of a solid.
In a preferred embodiment of the invention, the compound of formula (VII) is then subjected to reduction using hydrogen in the presence of Raney nickel in an ammoniacal ethanol medium and then converted into a salt using hydrochloric acid to yield the compound of formula (VIII):
Figure USRE046218-20161129-C00010
which is successively subjected to the action of sodium acetate and then acetic anhydride to yield the compound of formula (I), which is isolated in the form of a solid.
Alternatively, the compound of formula (VII) can be subjected to reduction by hydrogen in the presence of Raney nickel in a medium comprising acetic anhydride in a polar protic medium to yield the compound of formula (I), which is isolated in the form of a solid.
In a preferred compound of formula (III), Xa represents a group —S—C(S)—OC2H5.
In the processes according to the invention, initiation of the free radical reactions is carried out by thermal means. Preferably, the reaction mixture is heated to a temperature of from 50° C. to 140° C. Even more preferably, cyclisation is carried out at a temperature of from 130 to 135° C.
Peroxides are free radical initiators that are especially suitable for carrying out the step of addition of the compound of formula (II) to the compound of formula (III), or for performing cyclisation of the compound of formula (IV) to form the compound of formula (V). By way of example, there may be mentioned, especially, diisobutyryl peroxide, cumyl peroxyneodecanoate, tert-amyl peroxyneodecanoate, di(2-ethylhexyl)peroxydicarbonate, tert-butyl peroxyneodecanoate, dibutyl peroxydicarbonate, dicetyl peroxydicarbonate, dimyristyl peroxydicarbonate, tert-butyl peroxyneoheptanoate, tert-amyl peroxypivalate, didecanoyl peroxide, tert-amyl peroxy-2-ethylhexanoate, tert-butyl peroxyisobutyrate, 1,4-di(tert-butylperoxycarbo)cyclohexane, tert-butyl peroxyacetate, tert-butyl peroxybenzoate, di-tert-amyl peroxide, tert-butyl cumyl peroxide, bis(tert-butyl)peroxide, dicumyl peroxide, dilauroyl peroxide (DLP) or di(4-tert-butylcyclohexyl)peroxydicarbonate.
Preferably, the reaction is initiated in the presence of dilauroyl peroxide.
The amount of dilauroyl peroxide used in the cyclisation is preferably from 1 to 2.5 equivalents.
In a preferred embodiment of the invention, dilauroyl peroxide is added to the medium in stages.
The addition and/or cyclisation reactions are carried out in a solvent customarily used in free radical chemistry such as 1,2-dichloroethane, dichloromethane, benzene, toluene, trifluoromethylbenzene, chlorobenzene, hexane, cyclohexane, heptane, octane, ethyl acetate, tert-butyl alcohol, and mixtures thereof.
Preference is given to using ethyl acetate in the step of addition of the compound of formula (II) to the compound of formula (III), whilst cyclisation of the compound of formula (IV) to form the compound of formula (V) is advantageously carried out in chlorobenzene, ethyl acetate or ethyl butyrate. In this latter reaction, chlorobenzene is more especially preferred.
Conversion of the compound of formula (V) into the compound of formula (VI) is advantageously carried out in the presence of a Lewis acid such as aluminium isopropoxide or samarium isopropoxide. This conversion is moreover preferably carried out in an alcohol (primary or secondary), and even more preferably in isopropanol.
Preferably, a catalytic amount of p-toluenesulphonic acid is added to the mixture once all the tetralone (V) has been consumed at the end of conversion of the compound of formula (V) into the compound of formula (VI).
Aromatisation of compound (VI) is carried out in the presence of a quinone, preferably in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or tetrachlorobenzoquinone (TCQ). Even more preferably, aromatisation is carried out in the presence of TCQ at the reflux of toluene.
The compound of formula (II) is accessible to the person skilled in the art by means of conventional chemical reactions and/or chemical reactions described in the literature.
This process is especially valuable for the following reasons:
    • it makes it possible to obtain the compound of formula (I) on an industrial scale in good yields, starting from a simple, low-cost starting material;
    • only the intermediates of formulae (VI) and (VII) require a purification and isolation step.
The compounds of formulae (V) and (VI) obtained according to the process of the invention are new and useful as intermediates in the synthesis of agomelatine.
The Examples hereinbelow illustrate the invention without limiting it in any way. For the purpose of validating the reaction route, the synthesis intermediates were systematically isolated and characterised. However, it is possible to considerably optimise the procedures by limiting the number of intermediates isolated. Accordingly, Example 2 given hereinbelow corresponds to the same reaction route as that used in Example 1 but with the difference that only (7-methoxy-1,2-dihydro-1-naphthyl)acetonitrile and (7-methoxy-1-naphthyl)acetonitrile were isolated.
EXAMPLE 1 N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide Step A: S-[1-(cyanomethyl)-4-(4-methoxyphenyl)-4-oxobutyl]-O-ethyl dithiocarbonate
A solution of allyl cyanide (4.8 mL, 60.0 mmol) and S-[2-(4-methoxyphenyl)-2-oxoethyl]-O-ethyl dithiocarbonate1 (8.1 g, 30.0 mmol) in ethyl acetate (30 mL) is heated at reflux for 15 minutes under a nitrogen atmosphere. There is added, firstly, an amount of dilauroyl peroxide (10 mol %) to the solution under reflux. After 1 hour 30 minutes, another amount of dilauroyl peroxide (5 mol %) is also introduced. When the reagents have been completely consumed, the mixture is cooled to ambient temperature and concentrated under reduced pressure. The crude mixture is then purified by flash column chromatography (petroleum ether-ethyl acetate: 95-5 to 80-20) to yield the title compound in the form of an oil in a yield of 98%. 1S-[2-(4-methoxyphenyl)-2-oxoethyl]-O-ethyl dithiocarbonate is obtained according to the protocol described in Batanero, B. et al., J. Org. Chem. 2001, 66, 320.
1H NMR (δ, ppm) 7.93 (m, 2H, CH-4), 6.93 (m, 2H, CH-3), 4.67-4.57 (m, 2H, CH2-13), (CDCl3, 400 MHz) 3.99 (m, 1H, CH-9), 3.87 (s, 3H, CH3-1), 3.15 (t, 2H, J=7.3 Hz, CH2-7), 2.95 (dd, 2H, J=17.0, 6.0 Hz, CH2-10), 2.41-2.31 (m, 1H, CH2-8), 2.19-2.08 (m, 1H, CH2-8), 1.41 (t, 3H, J=7.1 Hz, CH3-14).
Step B: (7-Methoxy-4-oxo-1,2,3,4-tetrahydro-1-naphthyl)acetonitrile
The compound of Step A, used directly without having been purified, is redissolved in chlorobenzene (900 mL) and the solution is refluxed for 15 minutes under a nitrogen atmosphere. Dilauroyl peroxide is then gradually added to the solution under reflux (10 mol % every 10 minutes). When the reaction is complete, the mixture is cooled to ambient temperature and concentrated under reduced pressure. Acetonitrile is then introduced in order to cause a large part of the dilauroyl peroxide compounds to precipitate out. The mixture is then filtered, concentrated under reduced pressure and purified by flash column chromatography (petroleum ether-ethyl acetate: 60-40) to yield the title compound in solid form in a yield of 40%.
HRMS (EI, m/z) Calc. for C13H13NO2: 215.0946; found: 215.0946.
Step C: (7-Methoxy-1,2-dihydro-1-naphthyl)acetonitrile
Aluminium isopropoxide (2.05 g, 10.0 mmol) is added to a solution of the compound obtained in Step B (680 mg, 3.15 mmol) in isopropanol (15 mL) at ambient temperature. The reaction mixture is refluxed. When the reagents have been completely consumed, a few crystals of p-toluenesulphonic acid monohydrate are added and a Dean-Stark apparatus is mounted on top of the flask. The mixture is again refluxed for 1 hour, during which the isopropanol is gradually replaced with toluene by means of the Dean-Stark apparatus. A 1N HCl solution is then added and the resulting phases are separated. The aqueous phase is extracted with ethyl acetate, the organic phases being washed with saturated NaHCO3 solution and with saturated NaCl solution, then dried over MgSO4, filtered and concentrated under reduced pressure. The residue is purified by column chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in the form of an oil in a yield of 85%.
HRMS (EI, m/z) Calc. for C13H13NO: 199.0997. found: 199.1001.
Step D: (7-Methoxy-1-naphthyl)acetonitrile
Method A:
To a solution of the compound obtained in Step C (1.0 g, 5.0 mmol) in dichloromethane (50 mL) at ambient temperature there is added DDQ (1.4 g, 6.0 mmol). The reaction mixture is stirred for 2 days and is then washed with saturated NaHCO3 solution. The aqueous phase is extracted with ethyl acetate, the organic phase being washed with saturated NaCl solution, dried over MgSO4, filtered and concentrated under reduced pressure. The residue is purified by column chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in solid form in a yield of 55%.
Method B:
To a solution of TCQ (615 mg, 2.5 mmol) in toluene (1.5 mL) heated to 80° C. there is added the compound obtained in Step C (462 mg, 2.3 mmol) dissolved in toluene (3.5 mL). The mixture is then refluxed for 2.5 hours and is then diluted with water and extracted with petroleum ether. The organic phase is washed with NaOH solution (30% by weight) and with water and is then dried over MgSO4, filtered and concentrated under reduced pressure. The residue is purified by column chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in solid form in a yield of 61%.
HRMS (EI, m/z) Calc. for C13H11NO: 197.0841. found: 197.0838.
Step E: N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide
The reaction was carried out on a larger batch in order to optimise the yield obtained: 136 g of Raney nickel, 2.06 L of ethanol and 0.23 L of water are introduced into an 8 L reactor. Whilst stirring at 70° C. and under 30 bars of hydrogen, the compound obtained in Step D (0.8 kg) dissolved in acetic anhydride (2.4 L) is slowly added. At the end of the addition, the reaction mixture is stirred for 1 hour under hydrogen at 30 bar, the reactor is then decompressed and the liquors are filtered. After concentration of the mixture, the residue is crystallised from a mixture of ethanol/water 35/65 to yield the title product in a yield of 89% and with a chemical purity greater than 99%.
Melting point: 108° C.
EXAMPLE 2 N-[2-(7-ethoxy-1-naphthyl)ethyl]acetamide Step A: (7-Methoxy-1,2-dihydro-1-naphthyl)acetonitrile
A solution of allyl cyanide (6.75 mL, 84.0 mmol) and S-[2-(4-methoxyphenyl)-2-oxoethyl]-O-ethyl dithiocarbonate1 (11.3 g, 42.0 mmol) in ethyl acetate (45 mL) is heated at reflux for 15 minutes under a nitrogen atmosphere. There is added, firstly, an amount of dilauroyl peroxide (10 mol %) to the solution under reflux. After 1 hour 30 minutes, another amount of dilauroyl peroxide (5 mol %) is also introduced. When the reagents have been completely consumed, the mixture is cooled to ambient temperature and concentrated under reduced pressure. The crude mixture is redissolved in chlorobenzene (640 mL) and the solution is refluxed for 15 minutes under a nitrogen atmosphere. Dilauroyl peroxide is then gradually added to the solution under reflux (10 mol % every 10 minutes). When the reaction is complete, the mixture is cooled to ambient temperature and concentrated under reduced pressure. Acetonitrile is then introduced in order to cause a large part of the dilauroyl peroxide compounds to precipitate out. The mixture is then filtered and concentrated under reduced pressure. Half the crude oil thereby obtained is redissolved in isopropanol (100 mL) at ambient temperature in the presence of aluminium isopropoxide (13.6 g, 66.6 mmol). The reaction mixture is refluxed. When the reagents have been completely consumed, a few crystals of p-toluenesulphonic acid monohydrate are added and a Dean-Stark apparatus is mounted on top of the flask. The mixture is again refluxed for 2 hours, during which the isopropanol is gradually replaced with toluene by means of the Dean-Stark apparatus. A 1N HCl solution is then added and the resulting phases are separated. The aqueous phase is extracted with ethyl acetate, the organic phases being washed with saturated NaHCO3 solution and with saturated NaCl solution, then dried over MgSO4, filtered and concentrated under reduced pressure. The residue is purified by column chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in the form of an oil in a yield of 24%.
HRMS (EI, m/z) Calc. for C13H13NO: 199.0997. found: 199.1001.
Step B: (7-Methoxy-1-naphthyl)acetonitrile
The procedure is analogous to Step D of Example 1.
Step C: N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide
The procedure is analogous to Step E of Example 1.

Claims (18)

The invention claimed is:
1. A process for the synthesis of a compound of formula (I):
Figure USRE046218-20161129-C00011
wherein allyl cyanide of formula (II):
Figure USRE046218-20161129-C00012
is reacted, in the presence of a free radical initiator, with a compound of formula (III):
Figure USRE046218-20161129-C00013
wherein Xa represents a group —S—C(S)—OR in which R represents a linear or branched (C1-C6)alkyl group,
to yield the compound of formula (IV):
Figure USRE046218-20161129-C00014
wherein Xa is as defined hereinbefore,
wherein this latter compound may be optionally isolated, before being subjected to a cyclisation reaction in the presence of a free radical initiator in order to form the compound of formula (V):
Figure USRE046218-20161129-C00015
which compound of formula (V) may also be optionally isolated,
which compound of formula (V) is subjected to a reduction-dehydration reaction to yield the compound of formula (VI):
Figure USRE046218-20161129-C00016
which is then subjected to an aromatisation reaction to yield the compound of formula (VII):
Figure USRE046218-20161129-C00017
which is subjected to reduction using hydrogen in the presence of Raney nickel in a polar protic medium and to reaction with acetic anhydride to yield the compound of formula (I), which is isolated in the form of a solid.
2. The process according to claim 1, wherein the compound of formula (VII) is subjected to reduction using hydrogen in the presence of Raney nickel in an ammoniacal ethanol medium and then converted into a salt using hydrochloric acid to yield the compound of formula (VIII):
Figure USRE046218-20161129-C00018
which is successively subjected to the action of sodium acetate and then acetic anhydride to yield the compound of formula (I), which is isolated in the form of a solid.
3. The process according to claim 1, wherein the compound of formula (VII) is subjected to reduction by hydrogen in the presence of Raney nickel in a medium comprising acetic anhydride in a polar protie medium to yield the compound of formula (I), which is isolated in the form of a solid.
4. The process according to claim 1, wherein the group Xa represents —S—C(S)—OC2H5.
5. The process according to claim 1, wherein the free radical reactions are initiated by thermal means at a temperature of from 50 to 140° C.
6. The process according to claim 1, wherein cyclisation of the compound of formula (IV) is carried out at a temperature of from 130 to 135° C.
7. The process according to claim 1, wherein the step of addition of the compound of formula (II) to the compound of formula (III) and that of cyclisation of the compound of formula (IV) are initiated in the presence of dilauroyl peroxide.
8. The process according to claim 1, wherein the step of addition of the compound of formula (II) to the compound of formula (III) is carried out in chlorobenzene.
9. The process according to claim 1, wherein the step of cyclisation of the adduct of formula (IV) to form the compound of formula (V) is carried out in ethyl acetate.
10. The process according to claim 1, wherein the conversion of the compound of formula (V) into the compound of formula (VI) is carried out in the presence of aluminium isopropoxide.
11. The process according to claim 1, wherein the conversion of the compound of formula (V) into the compound of formula (VI) is carried out in isopropanol.
12. The process according to claim 1, wherein a catalytic amount of p-toluenesulphonic acid is added to the mixture at the end of conversion of the compound of formula (V) into the compound of formula (VI).
13. The process according to claim 1, wherein the aromatisation of the compound of formula (VI) is carried out in the presence of a quinone.
14. The process according to claim 1, wherein the aromatisation of the compound of formula (VI) is carried out in the presence of TCQ at the reflux of toluene.
15. A process for the synthesis of agomelatine starting from the compound of formula (V):
Figure USRE046218-20161129-C00019
wherein the compound of formula (V) is obtained according to the process according to claim 1.
16. A process for the synthesis of agomelatine starting from the compound of formula (VI):
Figure USRE046218-20161129-C00020
wherein the compound of formula (VI) is obtained according to the process according to claim 1.
17. A compound of formula (V):
Figure USRE046218-20161129-C00021
18. A compound of formula (VI):
Figure USRE046218-20161129-C00022
US14/619,284 2011-01-05 2012-01-04 Process for the synthesis of agomelatine Active USRE46218E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/619,284 USRE46218E1 (en) 2011-01-05 2012-01-04 Process for the synthesis of agomelatine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1100024 2011-01-05
FR1100024A FR2970000B1 (en) 2011-01-05 2011-01-05 NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN
PCT/FR2012/000005 WO2012113999A1 (en) 2011-01-05 2012-01-04 Process and intermediates for synthesizing agomelatine
US14/619,284 USRE46218E1 (en) 2011-01-05 2012-01-04 Process for the synthesis of agomelatine
US13/977,799 US8853449B2 (en) 2011-01-05 2012-01-04 Process for the synthesis of agomelatine

Publications (1)

Publication Number Publication Date
USRE46218E1 true USRE46218E1 (en) 2016-11-29

Family

ID=44088993

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/977,799 Ceased US8853449B2 (en) 2011-01-05 2012-01-04 Process for the synthesis of agomelatine
US14/619,284 Active USRE46218E1 (en) 2011-01-05 2012-01-04 Process for the synthesis of agomelatine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/977,799 Ceased US8853449B2 (en) 2011-01-05 2012-01-04 Process for the synthesis of agomelatine

Country Status (43)

Country Link
US (2) US8853449B2 (en)
EP (1) EP2661422B9 (en)
JP (1) JP5837616B2 (en)
KR (1) KR101543432B1 (en)
CN (1) CN103313965B (en)
AP (1) AP3609A (en)
AR (1) AR084780A1 (en)
AU (1) AU2012220474B2 (en)
BR (1) BR112013017307A2 (en)
CA (1) CA2823587C (en)
CL (1) CL2013001882A1 (en)
CO (1) CO6731101A2 (en)
CR (1) CR20130301A (en)
CU (1) CU24289B1 (en)
CY (1) CY1117774T1 (en)
DK (1) DK2661422T3 (en)
EA (1) EA022077B1 (en)
EC (1) ECSP13012735A (en)
ES (1) ES2583682T3 (en)
FR (1) FR2970000B1 (en)
GE (1) GEP20156365B (en)
HK (1) HK1189571A1 (en)
HR (1) HRP20160713T1 (en)
HU (1) HUE028471T2 (en)
IL (1) IL227281A (en)
JO (1) JO3200B1 (en)
ME (1) ME02408B (en)
MX (1) MX2013007837A (en)
MY (1) MY162977A (en)
NI (1) NI201300062A (en)
PE (1) PE20140037A1 (en)
PL (1) PL2661422T3 (en)
RS (1) RS54753B9 (en)
RU (1) RU2550812C2 (en)
SA (1) SA112330134B1 (en)
SG (1) SG191733A1 (en)
SI (1) SI2661422T1 (en)
TN (1) TN2013000274A1 (en)
TW (1) TWI438180B (en)
UA (1) UA104122C2 (en)
UY (1) UY33845A (en)
WO (1) WO2012113999A1 (en)
ZA (1) ZA201305027B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103058879B (en) * 2012-12-20 2015-09-09 安徽悦康凯悦制药有限公司 The preparation method of Agomelatine
CN103804232B (en) * 2014-01-26 2015-08-19 江西同和药业股份有限公司 A kind of 1-cyano group-1-(7-methoxyl-3,4-dihydro-1-naphthyl) methanol esters compounds and its preparation method and application
CN107353229B (en) * 2017-08-08 2019-04-30 许昌恒生制药有限公司 A kind of preparation method of agomelatine intermediate body

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447285A1 (en) 1990-02-27 1991-09-18 Adir Et Compagnie Naphthalene derivatives, procedure for their preparation and pharmaceutical compositions containing them
EP1564202A1 (en) 2004-02-13 2005-08-17 Les Laboratoires Servier Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these
US20050182267A1 (en) 2004-02-13 2005-08-18 Jean-Claude Souvie Process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and its application in the synthesis of agomelatine
CN101486665A (en) 2009-03-03 2009-07-22 上海医药工业研究院 Preparation of agomelatine intermediate 2-(7-methoxy-1-naphthyl) acetamide

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447285A1 (en) 1990-02-27 1991-09-18 Adir Et Compagnie Naphthalene derivatives, procedure for their preparation and pharmaceutical compositions containing them
US5318994A (en) 1990-02-27 1994-06-07 Adir Et Compagnie N-[2-(7-lower-alkoxynaphth-1-yl)ethyl]benzamides
EP1564202A1 (en) 2004-02-13 2005-08-17 Les Laboratoires Servier Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these
US20050182267A1 (en) 2004-02-13 2005-08-18 Jean-Claude Souvie Process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and its application in the synthesis of agomelatine
US7544839B2 (en) 2004-02-13 2009-06-09 Les Laboratoires Servier Process for the synthesis and crystalline form agomelatine
CN101486665A (en) 2009-03-03 2009-07-22 上海医药工业研究院 Preparation of agomelatine intermediate 2-(7-methoxy-1-naphthyl) acetamide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chu et al., Synthetic Communications 31(4), 2001, 621-629.
International Preliminary Report on Patentability Written Opinion for PCT/FR2012/000005, 2012.
International Preliminary Report on Patentability/Written Opinion for PCT/FR2012/000005 of Jul. 10, 2013.
International Search Report for PCT/FR2012/000005 of Mar. 8, 2012.
Kalinin et al., Journal of Organometallic Chemistry 383, 1990, 85-91.
Liard et al., Tetrahedron Letters 38(10), 1997, 1759-1762.

Also Published As

Publication number Publication date
WO2012113999A8 (en) 2013-08-01
CA2823587A1 (en) 2012-08-30
TWI438180B (en) 2014-05-21
AP2013007022A0 (en) 2013-07-31
NZ612173A (en) 2015-08-28
EA022077B1 (en) 2015-10-30
AP3609A (en) 2016-02-26
ZA201305027B (en) 2014-03-26
GEP20156365B (en) 2015-09-10
PL2661422T3 (en) 2016-10-31
CU24289B1 (en) 2017-12-08
CO6731101A2 (en) 2013-08-15
CR20130301A (en) 2013-08-08
US20130289307A1 (en) 2013-10-31
ES2583682T3 (en) 2016-09-21
CA2823587C (en) 2015-11-24
HK1189571A1 (en) 2014-06-13
UY33845A (en) 2012-07-31
TW201309623A (en) 2013-03-01
AU2012220474A1 (en) 2013-07-11
MX2013007837A (en) 2013-09-06
SI2661422T1 (en) 2016-08-31
KR20130115345A (en) 2013-10-21
ES2583682T9 (en) 2016-10-31
KR101543432B1 (en) 2015-08-10
WO2012113999A1 (en) 2012-08-30
MY162977A (en) 2017-07-31
CN103313965B (en) 2015-08-05
EP2661422A1 (en) 2013-11-13
ECSP13012735A (en) 2013-09-30
AU2012220474B2 (en) 2015-08-20
BR112013017307A2 (en) 2016-10-04
CY1117774T1 (en) 2017-05-17
ME02408B (en) 2016-09-20
SA112330134B1 (en) 2014-08-25
RU2550812C2 (en) 2015-05-20
DK2661422T3 (en) 2016-10-24
RS54753B9 (en) 2019-09-30
CU20130092A7 (en) 2013-08-29
JP5837616B2 (en) 2015-12-24
UA104122C2 (en) 2013-12-25
FR2970000A1 (en) 2012-07-06
RU2013136344A (en) 2015-02-10
IL227281A (en) 2015-06-30
HUE028471T2 (en) 2016-12-28
EP2661422B1 (en) 2016-04-20
AR084780A1 (en) 2013-06-26
JO3200B1 (en) 2018-03-08
PE20140037A1 (en) 2014-02-01
SG191733A1 (en) 2013-08-30
EA201300794A1 (en) 2014-02-28
IL227281A0 (en) 2013-09-30
HRP20160713T1 (en) 2016-07-29
RS54753B1 (en) 2016-10-31
CN103313965A (en) 2013-09-18
FR2970000B1 (en) 2013-01-04
US8853449B2 (en) 2014-10-07
NI201300062A (en) 2013-12-11
CL2013001882A1 (en) 2013-12-06
JP2014509309A (en) 2014-04-17
EP2661422B9 (en) 2016-09-07
TN2013000274A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
JP5112399B2 (en) A novel method for synthesis of agomelatine
US20090131719A1 (en) Process for the synthesis of (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine
USRE46218E1 (en) Process for the synthesis of agomelatine
NZ612173B2 (en) Process and intermediates for synthesizing agomelatine
US8871975B2 (en) Process for the synthesis of agomelatine
OA16477A (en) New process for the synthesis of agomelatine.
NZ612163B2 (en) New process for the synthesis of agomelatine

Legal Events

Date Code Title Description
CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8